Evidence of drug-response heterogeneity rapidly generated from a single cancer cell

Rong Wang; Chengmeng Jin; Xun Hu

doi:10.18632/oncotarget.17064

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Evidence of drug-response heterogeneity rapidly generated from a single cancer cell

Rong Wang, Chengmeng Jin and Xun Hu _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:41113-41124. https://doi.org/10.18632/oncotarget.17064

Metrics: PDF 1754 views | HTML 2234 views | ?

Abstract

Rong Wang1,*, Chengmeng Jin1,* and Xun Hu1

1Cancer Institute, A Key Laboratory For Cancer Prevention & Intervention, Ministry of Education of the People’s Republic of China, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

*These authors have contributed equally to this work

Correspondence to:

Xun Hu, email: [email protected]

Keywords: heterogeneity, cancer, drug-response

Received: November 04, 2016 Accepted: March 07, 2017 Published: April 12, 2017

ABSTRACT

One cancer cell line is believed to be composed of numerous clones with different drug sensitivity. We sought to investigate the difference of drug-response pattern in clones from a cell line or from a single cell. We showed that 22 clones derived from 4T1 cells were drastically different from each other with respect to drug-response pattern against 11 anticancer drugs and expression profile of 19 genes associated with drug resistance or sensitivity. Similar results were obtained using daughter clones derived from a single 4T1 cell. Each daughter clone showed distinct drug-response pattern and gene expression profile. Similar results were also obtained using Bcap37 cells. We conclude that a single cancer cell can rapidly produce a population of cells with high heterogeneity of drug response and the acquisition of drug-response heterogeneity is random.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 17064

Publication Alerts

Research Papers:

Evidence of drug-response heterogeneity rapidly generated from a single cancer cell

Abstract